Compass Therapeutics
NASDAQ: CMPXCambridge, US · Founded 2014 · Incorporated in Delaware · 61 employees on LinkedIn · 6 known investors
Find your way into Compass Therapeutics
729 people in our graph share verified history with the Compass Therapeutics team — schools, employers, funds. One of them is your warm intro.
Ren Rileyunlockedknows Errik Anderson · together at Dartmouth College (overlapped)
knows the team · via Dartmouth College
knows the team · via Alumni Ventures
×4knows the team · via Massachusetts General Hospital
knows the team · via Dana-Farber Cancer Institute
×2knows the team · via Xavier University
Compass Therapeutics uses proprietary antibody discovery platforms to generate and screen diverse panels of monoclonal and multispecific antibodies, aiming to identify synergistic therapeutic combinations. Its pipeline focuses on immuno-oncology therapies that bridge the innate and adaptive immune systems by targeting T cells, NK cells, and macrophages.
Founders & leadership
Compass Therapeutics was founded in 2014 by Schuetz Thomas, Errik Anderson, and Thomas J. Schuetz.
ST
Schuetz ThomasinCo-Founder, CEO, Vice Chairman of the BoardThomas Schuetz is a biotechnology executive with experience in venture capital, board roles, and management; he has built clinical operations at early- and late-stage biotech companies.
EA
Errik AndersoninCo-FounderErrik Anderson is an executive officer and director at Compass Therapeutics, which develops monoclonal and multispecific antibodies for immuno-oncology applications targeting innate and adaptive immune pathways. He has experience as an entrepreneur, mentor, and investor in the biotech and technology sectors.
TJ
Thomas J. SchuetzinCo-Founder, CEO, Vice Chairman of the BoardThomas J. Schuetz is an Executive Officer and Director at Compass Therapeutics, an immuno-oncology company that uses antibody discovery platforms to develop multispecific therapeutic combinations. He has held senior biotechnology leadership roles at early and late-stage companies, with experience in venture capital and board management.
VB
Vered Bisker-LeibinAdvisor
Board
CL
Carl L. GordonBoard director
JS
Julie SunderlandBoard director
SP
Stephen P. SquintoBoard director
PF
Philip FerneauBoard director
ST
Steve TregayBoard director
Investors · 6
Reported raises · per SEC filings
Form D private placements$388.4M disclosed across 5 rounds · 2014–2020
▶$195.3MraisedJul 2020 · 114 investors · OtherRule 506(b)
▶$195.3MraisedJul 2020 · 114 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Vered Bisker-LeibExecutive Officer
- Carl L. GordonDirector
- Julie SunderlandDirector
- Stephen P. SquintoDirector
- Philip FerneauDirector
- Thomas J. SchuetzExecutive Officer, Director
- Offering amount
- $195.3M
- Amount sold
- $195.3M
- First sale
- Jun 2020
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$60.5MraisedJul 2020 · 110 investors · OtherRule 506(b)
▶$60.5MraisedJul 2020 · 110 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Stephen P. SquintoDirector
- Julie SunderlandDirector
- Thomas J. SchuetzExecutive Officer, Director
- Vered Bisker-LeibExecutive Officer
- Carl L. GordonDirector
- Philip FerneauDirector
- Offering amount
- $70M
- Amount sold
- $60.5M
- Sales commissions
- $4.7M
- Placement agents
- Katalyst Securities LLC, B. Riley FBR, Inc., Raymond James & Associates, Inc.
- First sale
- Jun 2020
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$110.2MraisedJul 2018 · 20 investors · BiotechnologyRule 506(b)
▶$110.2MraisedJul 2018 · 20 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- VERED BISKER-LEIBExecutive Officer
- TIMOTHY ANDERSONDirector
- PIOTR BOBROWICZExecutive Officer
- PHILIP FERNEAUDirector
- CARL GORDONDirector
- DAMON BANKSExecutive Officer
- THOMAS J. SCHUETZExecutive Officer, Director, Promoter
- STEVEN SQUINTODirector
- ERRIK ANDERSONDirector, Promoter
- SARA MANNLEExecutive Officer
- JEB LEDELLExecutive Officer
- STEVE TREGAYDirector
- BEN AUSPITZDirector
- Offering amount
- $170.2M
- Amount sold
- $110.2M
- Proceeds to insiders
- $1.7M
- First sale
- Jun 2015
- Incorporated
- Limited Liability Company, Delaware, 2014
- Federal exemptions
- 06b
▶$21.8MraisedJan 2018 · 14 investors · BiotechnologyRule 506(b)
▶$21.8MraisedJan 2018 · 14 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- THOMAS J SCHUETZExecutive Officer, Director, Promoter
- STEVEN SQUINTODirector
- CARL GORDONDirector
- SARA MANNLEExecutive Officer
- VERED BISKER-LEIBExecutive Officer
- ERRIK ANDERSONDirector, Promoter
- BEN AUSPITZDirector
- BRUCE STEELDirector
- JEB LEDELLExecutive Officer
- DAMON BANKSExecutive Officer
- WILL EDENDirector
- PIOTR BOBROWICZExecutive Officer
- STEVE TREGAYDirector
- PHILIP FERNEAUDirector
- Offering amount
- $50M
- Amount sold
- $21.8M
- First sale
- Dec 2017
- Incorporated
- Limited Liability Company, Delaware, 2014
- Federal exemptions
- 06b
▶$575KraisedMay 2015 · 4 investors · BiotechnologyRule 506(b)
▶$575KraisedMay 2015 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Schuetz ThomasExecutive Officer, Director
- Errik AndersonExecutive Officer, Director
- Steve TregayDirector
- Offering amount
- $1M
- Amount sold
- $575K
- First sale
- May 2014
- Incorporated
- Limited Liability Company, Delaware, 2014
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlap
Seeking Alpha33 shared keywordsSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
Compass (NYSE:COMP)32 shared keywordsCompass is a real estate brokerage that uses technology to help consumers find homes. The company serves residential real estate buyers and sellers in the United States.
Companies competing with Compass Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Compass Therapeutics Q2 Earnings: $25.2M Net Loss | CMPX Stock Newsstocktitan.net · Aug 2026
Compass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate Update | The Manila Timesmanilatimes.net · Aug 2026Frequently asked questions
- What does Compass Therapeutics do?
- Compass Therapeutics uses proprietary antibody discovery platforms to generate and screen diverse panels of monoclonal and multispecific antibodies, aiming to identify synergistic therapeutic combinations. Its pipeline focuses on immuno-oncology therapies that bridge the innate and adaptive immune systems by targeting T cells, NK cells, and macrophages.
- Who founded Compass Therapeutics?
- Compass Therapeutics was founded by Schuetz Thomas, Errik Anderson, Thomas J. Schuetz in 2014.
- Who are Compass Therapeutics's investors?
- Compass Therapeutics's investors include BioBrit, F-Prime Capital, Foresite Capital, OrbiMed, venBio Partners, Vivo Capital.
- How much funding has Compass Therapeutics raised?
- Compass Therapeutics has disclosed $388.4M raised across 5 rounds.
- Where is Compass Therapeutics headquartered?
- Compass Therapeutics is headquartered in Cambridge, US.